ClinicalTrials.gg

Multiple Sclerosis, Chronic Progressive clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 245 studies for Multiple Sclerosis, Chronic Progressive across more than 10 countries. 54 are recruiting or about to start. 160 of them are mainly about Multiple Sclerosis, Chronic Progressive (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Completed
122
Recruiting
39
Active, not recruiting
20
Status unknown
19
Terminated
19
Not yet recruiting
12

Phase

Phase 2
75
Phase 1
57
Phase 3
39
Phase 4
5
Early Phase 1
4

Where

United States
105
United Kingdom
35
Germany
32
France
32
Canada
31
Spain
29

Who develops what

Add Multiple Sclerosis, Chronic Progressive to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 13 companies, 13 with this as their studies’ main aim; 3 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Hoffmann-La Roche, AbelZeta and Novartis here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
bendamustineRecent, limited
Evidence
  • NCT07477639 · Tr1X, Inc. · Phase 2 · live · background · “Bendamustine” · registered Mar 2026
Teva Pharmaceutical Industries, Ltd.25% of its industry studiesUS: off-patent, 3 generics marketed11 study
MethylprednisoloneRecent, limited
Evidence
  • NCT05232825 · Hoffmann-La Roche · Phase 3 · comparator · “Methylprednisolone IV” · registered Jan 2022
  • NCT04548999 · Hoffmann-La Roche · Phase 3 · live · background · “Methylprednisolone” · registered Sep 2020
Pfizer17% of its industry studiesUS: off-patent, 3 generics marketed11 study
Immunosuppressive AgentsRecent, limited
Evidence
  • NCT06384976 · Kyverna Therapeutics · Phase 2 · live · background · “Standard lymphodepletion regimen” · registered Nov 2023
—11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
orelabrutinib☆ Track2 live phase-3 studies: NCT07299019, NCT07067463Zenas BioPharma (USA), LLC
remibrutinibApproved: US 2025 · EU 2026☆ Track1 live phase-3 study: NCT07225504Novartis
ocrelizumabApproved: US 2017 · EU 2018☆ Track3 live phase-3 studies: NCT04548999, NCT03523858, NCT04035005Hoffmann-La Roche

The 3 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jun 2027 est.SUN-627 · Sundance Biosciences, Inc. · Phase 2 main aimNCT07840326 A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) — primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) compared to placebo · 20 enrolled
  • 1 Oct 2027 est.NG01 · NeuroGenesis Ltd. · Phase 2 main aimNCT06961383 Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis — primary endpoint: Walking Ability · 45 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Multiple Sclerosis, Chronic Progressive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 open · Antimetabolites 1 open · Corticosteroids 4

Coming up

18studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (15%) take healthy volunteers.

Recruiting studies that take each age, of 39
AgeWomenMen
100 (0%)0 (0%)
1835 (90%)35 (90%)
3037 (95%)37 (95%)
4038 (97%)38 (97%)
5039 (100%)39 (100%)
6530 (77%)30 (77%)
7518 (46%)18 (46%)
859 (23%)9 (23%)

Across all 245 studies, recruiting or not: 73% stop at 75 or younger and 56% at 65; 2% take children; <1% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Multiple Sclerosis, Chronic Progressive studies take

Of 25 phase 2 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 39 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 144 mo17–56 · 21 studies——
Phase 239 mo23–55 · 25 studies——
Phase 361 mo52–83 · 20 studies——
Interventional, no phase33 mo18–44 · 36 studies—33 mo18–44 · 35 studies
Observational37 mo34–87 · 18 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 245. Browse all 245 → or search them.